Impel NeuroPharma Inc.

-0.10 (-1.12%)
Earnings Announcements

Impel Neuropharma Reports $1.24 Q3 Loss Per Share

Published: 11/15/2021 13:24 GMT
Impel NeuroPharma Inc. (IMPL) - Impel Neuropharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update.
Q3 Non-GAAP Loss per Share $1.23.
Q3 GAAP Loss per Share $1.24.
Increased Cash Position and Extended Runway Into 2023 With Follow-on Equity Offering of 3.45 Million Shares Valued at $51.8 Million.
Revenue is expected to be $1.66 Million
Adjusted EPS is expected to be -$0.86

Next Quarter Revenue Guidance is expected to be $3.7 Million
Next Quarter EPS Guidance is expected to be -$0.90

More details on our Analysts Page.